Suppr超能文献

熊去氧胆酸在肝脏疾病中的应用。

Use of ursodeoxycholic acid in liver diseases.

作者信息

Kumar D, Tandon R K

机构信息

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi.

出版信息

J Gastroenterol Hepatol. 2001 Jan;16(1):3-14. doi: 10.1046/j.1440-1746.2001.02376.x.

Abstract

Ursodeoxycholic acid is currently the only established drug for the treatment of chronic cholestatic liver diseases. It has cytoprotective, anti-apoptotic, membrane stabilizing, anti-oxidative and immunomodulatory effects. Prolonged administration of ursodeoxycholic acid in patients with primary biliary cirrhosis (PBC) is associated with survival benefit and a delaying of liver transplantation. There is evidence that it might even prevent progression of the histologic stage of PBC. It also has a beneficial effect on primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, liver disease associated with cystic fibrosis, chronic graft versus host disease, total parenteral nutrition associated cholestasis and various pediatric cholestatic liver diseases. In the present review the current knowledge about the mechanisms of the action and role of ursodeoxycholic acid in the treatment of various liver diseases has been discussed.

摘要

熊去氧胆酸是目前唯一已确定用于治疗慢性胆汁淤积性肝病的药物。它具有细胞保护、抗凋亡、膜稳定、抗氧化和免疫调节作用。在原发性胆汁性肝硬化(PBC)患者中长时间使用熊去氧胆酸与生存获益及肝移植延迟有关。有证据表明它甚至可能阻止PBC组织学阶段的进展。它对原发性硬化性胆管炎、妊娠期肝内胆汁淤积症、与囊性纤维化相关的肝病、慢性移植物抗宿主病、全胃肠外营养相关胆汁淤积以及各种儿童胆汁淤积性肝病也有有益作用。在本综述中,已讨论了关于熊去氧胆酸在治疗各种肝病中的作用机制和作用的现有知识。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验